BB&T Securities’s Myriad Genetics MYGN Stock Holding History

BB&T Securities’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,000	Closed	-$361K	–	1496
2017 Q3	$361K	Buy	+10,000	New	+$285K	﹤0.01%	1090

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BB&T Securities's MYGN Position: Q4 2018 in Review

BB&T Securities sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 5,543 shares — an estimated $254K sold.

BB&T Securities first reported a position in MYGN in Q2 2013 and held it in 20 quarters. The position peaked at $27.4M in Q3 2015. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

BB&T Securities reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
BB&T Securities sold 5,543 Myriad Genetics shares in Q4 2018, an estimated $254K.
BB&T Securities first reported a position in Myriad Genetics in Q2 2013 and held it in 20 quarters.
BB&T Securities's Myriad Genetics position peaked at $27.4M in Q3 2015.
264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on BB&T Securities's 13F filing for Q4 2018, filed 4 Feb 2019.